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The pathogenesis of Systemic Sclerosis (SSc) is extremely complex, and despite extensive studies, the exact mechanisms involved are
not well understood. Numerous recent studies of early events in SSc pathogenesis have suggested that unknown etiologic factors in
a genetically receptive host trigger structural and functional microvascular endothelial cell abnormalities. These alterations result
in the attraction, transmigration, and accumulation of immune and inflammatory cells in the perivascular tissues, which in turn
induce the phenotypic conversion of endothelial cells and quiescent fibroblasts into activated myofibroblasts, a process known as
endothelial to mesenchymal transition or EndoMT. The activated myofibroblasts are the effector cells responsible for the severe
and frequently progressive fibrotic process and the fibroproliferative vasculopathy that are the hallmarks of SSc. Thus, according to
this hypothesis the endothelial and vascular alterations, which include the phenotypic conversion of endothelial cells into activated
myofibroblasts, play a crucial role in the development of the progressive fibrotic process affecting skin and multiple internal organs.
The role of endothelial cell and vascular alterations, the potential contribution of endothelial to mesenchymal cell transition in the
pathogenesis of the tissue fibrosis, and fibroproliferative vasculopathy in SSc will be reviewed here.

1. Introduction
Scleroderma or Systemic Sclerosis (SSc) is an autoimmune
disease of unknown etiology characterized by progressive
fibrosis of skin and multiple internal organs and prominent
and often severe alterations in the microvasculature [1].
Although SSc is the third most common systemic inflammatory autoimmune disease and has the highest case-specific
mortality among this group of idiopathic disorders, there
is currently no effective disease-modifying therapy for SSc.
Therefore, there is an urgent unmet need for the development
of effective disease-modifying therapies to improve the devastating health consequences and high mortality caused by
the disease. The cells responsible for the severe fibroproliferative process in SSc are activated myofibroblasts, a unique
population of mesenchymal cells displaying unique biological
functions including increased production of fibrillar type l
and type lll collagens, initiation of expression of 𝛼-smooth
muscle actin (𝛼-SMA), a molecular marker of activated

myofibroblasts, and reduction in the expression of genes
encoding extracellular matrix (ECM)-degradative enzymes.
The accumulation of myofibroblasts in affected tissues and
the persistence of their elevated biosynthetic functions are
crucial determinants of the extent and rate of progression
of the fibrotic process in SSc, and of its clinical course,
response to therapy, prognosis, and overall mortality. The
origins of the myofibroblasts responsible for the exaggerated
and uncontrolled production of collagen and other ECM
proteins in SSc have not been completely elucidated. Extensive research studies have shown that these cells originate
from several sources, including expansion of resident tissue
fibroblasts and migration and tissue accumulation of bone
marrow-derived circulating fibrocytes, or from epithelial cells
which have undergone epithelial to mesenchymal transition
(EMT). More recent studies, however, have demonstrated
that endothelial cells are also capable of undergoing endothelial to mesenchymal transition (EndoMT) and that this
transition might be an important source of the mesenchymal
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cells participating in the fibroproliferative vasculopathy and
the fibrotic process in SSc. Thus, this novel mechanism
of generation of activated myofibroblasts may represent an
important and currently unexplored target for the development of disease-modifying therapeutic interventions for this
currently incurable disease.

immunological abnormalities and the cytokine, chemokine,
and growth factor abnormalities, all of which play an extremely important role in SSc pathogenesis, will not be
reviewed here owing to the availability of numerous outstanding reviews about these topics that have been recently
published [15–22].

2. SSc Pathogenesis: Overview

3. Vascular Abnormalities in SSc

The pathogenesis of SSc is extremely complex, and despite
numerous studies that examined several aspects of its intricate picture, the exact mechanisms involved are not well
understood. However, it is apparent that the clinical and
pathologic manifestations of the disease are the result of three
distinct processes: (1) fibroproliferative vascular lesions of
small arteries and arterioles, (2) excessive and often progressive deposition of collagen and other ECM macromolecules
in skin and various internal organs, and (3) alterations
of humoral and cellular immunity characterized by innate
immunity alterations, involvement of macrophages and Tand B-lymphocytes, and the production of numerous diseasespecific autoantibodies [2–4]. It has not been established
which of these processes is of primary importance or how
they are temporally related during the development and
progression of the disease. However, numerous recent studies
have clarified some of the early events in SSc pathogenesis
[5–11]. A current hypothesis for SSc pathogenesis posits
that there is a sequence of pathogenetic events initiated
by unknown etiologic factors in a genetically receptive
host which trigger microvascular injury characterized by
structural and functional endothelial cell abnormalities. The
endothelial cell abnormalities result in the increased production and release of numerous and potent mediators including cytokines, chemokines, polypeptide growth factors, and
various other substances such as nitric oxide, prostaglandins,
reactive oxygen species (ROS), and thrombogenic and procoagulant activities or in the reduction of important compounds such as prostacyclin. The endothelial cell dysfunction
triggers the chemokine and cytokine-mediated attraction
of specific inflammatory cellular elements from the bloodstream and bone marrow and their transmigration into the
surrounding tissues. These events lead to the establishment
of a chronic inflammatory process with participation of
macrophages and T- and B-lymphocytes, with further production and secretion of cytokines and growth factors that
induce the tissue accumulation of activated myofibroblasts,
the effector cells responsible for the fibrotic process [12–
14]. This sequence of events, diagrammatically illustrated
in Figure 1, results in the development of a severe and
often progressive fibroproliferative vasculopathy and in the
exaggerated and widespread accumulation of fibrotic tissue
in the skin and multiple internal organs, which are the most
salient characteristics of the disease.
The purpose of this review is to discuss recent studies that
have substantially advanced the current understanding of
SSc pathogenesis regarding the endothelial cell and vascular
abnormalities and the role of endothelial to mesenchymal
transition (EndoMT) in the pathogenesis of this currently
incurable disease. However, the genetic, innate, and acquired

Vascular dysfunction is one of the earliest and most noticeable manifestations of SSc as indicated by the occurrence
of Raynaud phenomenon, nailfold capillary microvascular
alterations, and digital ulcers almost universally in SSc
patients often preceding the appearance of clinical evidence
of tissue fibrosis [23, 24]. Furthermore, there is a remarkable microvascular fibroproliferative vasculopathy present
in essentially all SSc affected organs that is responsible for
the most important symptoms and clinical manifestations
of SSc and often leads to serious and even fatal complications. Although the effects of vascular abnormalities and
dysfunction in patients with SSc are most dramatic when
they involve the pulmonary and renal arterioles, causing
renal crisis [25, 26] and pulmonary artery hypertension [27–
29], respectively, there are numerous other important clinical
manifestations of the disease that are caused or mediated by
the prominent fibroproliferative vasculopathy. These include
capillary rarefaction and capillary loop dilation in the nailfold
capillaries [30, 31], cutaneous and mucosal telangiectasias
[32–34], erectile dysfunction resulting from alterations in
penile blood flow [35–37], and cardiac dysfunction including nonartherosclerotic myocardial infarcts [38, 39], gastric
antral vascular ectasia [40–42], central retinal artery occlusion [43, 44], and involvement of larger vessels [45, 46].
Histopathologically, the affected vessels display marked narrowing or even complete occlusion of the vessel lumen with
remarkable accumulation of mesenchymal cells and fibrous
tissue in the subendothelial compartment and associated
endothelial cell abnormalities, which include swelling and
apoptotic changes, as well as thickening of the basement
membrane. Occasionally, endothelial cell detachment and
intravascular platelet thrombi are found. On transmission,
electron microscopy universal morphological changes of
endothelial cells and basement membrane duplication and
lamellation are characteristic alterations. The histopathological changes in the microvasculature of several affected organs
are illustrated in Figure 2.

4. Mechanisms of Vascular and Endothelial
Cell Injury in SSc
The initial events responsible for the vascular and endothelial cell injury and their subsequent activation are not
known although numerous putative etiologic factors have
been suggested. Some of these include exogenous chemical substances, vasculotropic viral pathogens, antiendothelial cell antibodies, cellular products from inflammatory
cells, tissue hypoxia, or ROS generated during episodes of
ischemia/reperfusion [8–10, 47–52]. The injured/activated
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Figure 1: Overall scheme illustrating a current understanding of SSc pathogenesis. Hypothetical sequence of events involved in tissue fibrosis
and fibroproliferative vasculopathy in SSc. An unknown causative agent induces activation of immune and inflammatory cells in genetically
predisposed hosts resulting in chronic inflammation. Activated inflammatory and immune cells secrete cytokines, chemokines, and growth
factors which cause fibroblast activation, differentiation of endothelial and epithelial cells into myofibroblasts, and recruitment of fibrocytes
from the bone marrow and the peripheral blood circulation. The activated myofibroblasts produce exaggerated amounts of ECM resulting in
tissue fibrosis.

endothelial cells may undergo apoptosis or may detach from
the vascular endothelium, leaving a denuded vascular lumen
which triggers the release of endothelial cell precursors
from the bone marrow in attempts to repair the endothelial
lining defects. Supporting this notion are the observations

of increased numbers of circulating endothelial cells and
endothelial cell precursors in SSc patients [53–55]. The
activation of endothelial cells also induces the expression of
cell adhesion molecules such as ICAM, VCAM-1, and Eselectin [56, 57]. The induced expression of cell adhesion
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Figure 2: Histopathology of fibroproliferative vasculopathy in small vessels of various affected organs. Histopathology of microvascular
arterioles from SSc lung, kidney, and retinal vessels displaying prominent endothelial fibroproliferative alterations causing severe narrowing
of vessel lumen and thickening of vessel walls.

molecules by the endothelial cells leads to recruitment and
activation of chronic inflammatory cells, including T- and
B-lymphocytes and profibrotic macrophage populations and
their accumulation in the perivascular tissue and in the interstitium of parenchymal organs. The activated chronic inflammatory cells are responsible for the increased production
of transforming growth factor-𝛽 (TGF-𝛽), connective tissue
growth factor (CTGF), and other profibrotic polypeptide
growth factors which together with the mediators released
by the endothelial cells, such as endothelin-1, induce subsequent pathogenetic events leading to the severe tissue
fibrosis and fibroproliferative vasculopathy characteristic of
the disease [1–11]. Besides the endothelial cell abnormalities,
other vascular alterations include increased proliferation of
smooth muscle cells in the medial layer of affected vessels,
marked accumulation of fibrotic tissue in the subendothelial
compartment, and initiation of platelet aggregation and
intravascular thrombosis, eventually causing microvascular
occlusion [58, 59]. These multiple events result in tissue
hypoxia which can cause activation of hypoxia-dependent
profibrogenic processes, including further increases in production of TGF-𝛽 and interstitial collagens as well as other
ECM macromolecules [60, 61]. In addition to the structural
vascular changes described above, there are also functional
vascular alterations which include a reduction in endothelium dependent vasodilator molecules and dysfunction of
the neurovascular and neuroendothelial control of vasodilation [62–65], as well as a relative deficiency of vasodilator
molecules such as prostacyclin and nitric oxide.
The injured or cytokine/growth factor-activated endothelial cells also produce increased amounts of the potent profibrotic and vasoconstrictor polypeptide, endothelin-1 [66, 67],

and numerous other vasoactive and prothrombogenic compounds that are capable of directly stimulating various target
cells such as vascular smooth muscle cells and fibroblasts [8–
10, 66, 67]. The important role of endothelin-1 in the development of SSc-associated tissue fibrosis and fibroproliferative vasculopathy has received increasing attention recently.
Indeed, elevated levels of endothelin-1 have been found in
plasma and bronchoalveolar lavage of SSc patients [68–70]
and correlate with clinical parameters and subsets of the
disease [71, 72]. Numerous studies have demonstrated that
endothelin-1 is a potent inducer of proliferation and ECM
production by fibroblastic cells [73–76]. The exaggerated
vasoconstrictor response to the increased endothelin levels
causes vascular hypoxia and further endothelial injury, thus
establishing and maintaining a vicious cycle of endothelial
injury and fibrosis. The chronic inflammatory cells accumulated in the perivascular environment also participate
in the maintenance of a powerful profibrotic cycle since
the numerous cytokines, chemokines, and growth factors
they produce can in turn induce further activation of the
endothelial cells and their production of profibrotic mediators [67]. The mutual interaction between inflammatory and
endothelial cells has been validated by a recent study describing the upregulation of endothelin-1 and TGF-𝛽 in human
microvascular endothelial cells induced by interferon-𝛾, one
of the potent cytokines released by the infiltrating inflammatory cells [77]. Additional alterations which contribute to
the severe vascular dysfunction and rarefaction in SSc are
the result of disordered angiogenesis [78–84] and impaired
differentiation of bone marrow stem cells into endothelial
cells [85].
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5. Endothelial to Mesenchymal Transition
(EndoMT) in the Pathogenesis of SSc
One of the most characteristic histopathologic alterations in
SSc is a severe fibroproliferative vasculopathy affecting the
microvasculature as well as some larger vessels [86]. The
proliferative vasculopathy of SSc has two distinct components. The first one is a marked proliferation of smooth
muscle cells in the media of medium size and small size
arterioles, a process which plays a crucial role in SScassociated pulmonary hypertension. The second component
is most prominent in the small arterioles of parenchymal
organs, such as the lungs and kidneys, and is characterized
by the subendothelial accumulation of activated fibroblasts
or myofibroblasts and the production of abundant fibrotic
tissue. The origin of mesenchymal cells responsible for the
fibrotic microvascular occlusion in SSc is not known, but
recent studies have suggested that at least some of these
cells may result from EndoMT, that is, the transdifferentiation of endothelial cells into subintimal fibroblasts induced
by locally-secreted cytokines and growth factors. During
EndoMT, endothelial cells lose their specific endothelial cell
markers, such as vascular endothelial cadherin (VE cadherin)
and von Willebrand factor, and acquire a mesenchymal or
myofibroblastic phenotype initiating expression of 𝛼-SMA,
vimentin, and type I collagen. In addition, these cells become
motile and are capable of migrating into surrounding tissues.
EndoMT has been described as an important process during
cardiac valve and pulmonary artery embryonic development
[87–89]. More recently, EndoMT has emerged as a possible
mechanism in the pathogenesis of tissue fibrosis in various diseases, including diabetic nephropathy, cardiac fibrosis, intestinal fibrosis, portal hypertension, and pulmonary
hypertension [90–100]. Although there is some experimental
evidence supporting the participation of EndoMT in SSc, further studies will be required to conclusively demonstrate that
EndoMT plays a role in the pathogenesis of SSc-associated
fibroproliferative vasculopathy and progressive tissue fibrosis.
A firm demonstration of the occurrence of EndoMT in SSc
and a further understanding of the molecular mechanisms
involved may lead to the pharmacologic modulation or
abrogation of this pathway in SSc.

6. Molecular Mechanisms of EndoMT
The molecular mechanisms involved in the EndoMT process
have not been fully elucidated, and despite the remarkable
importance of this process to normal development and to
various pathologic conditions including SSc, only a few studies have examined the molecular changes and the regulatory
events occurring in endothelial cells during their transdifferentiation into mesenchymal cells or myofibroblasts. However,
substantial recent evidence has accumulated demonstrating
the crucial role of TGF-𝛽 signaling [101–104] in the initiation
of EndoMT during normal development as well as in various
diseases.

5
6.1. Role of TGF-𝛽 in EndoMT. TGF-𝛽 is a pleiotropic growth
factor involved in numerous physiologic and pathologic processes including embryogenesis, cellular development and
differentiation, immunologic system development, inflammatory response functions, and wound repair [105–107].
TGF-𝛽 plays a key role in the pathogenesis of fibrotic diseases
by stimulating the production of various collagens and other
ECM components by mesenchymal cells and by inhibiting the
expression of various relevant metalloproteinases [103, 104,
108–114]. Although the precise mechanisms mediating the
potent profibrotic effects of TGF-𝛽 have not been completely
elucidated, it appears that TGF-𝛽 may cause the establishment of an autocrine signaling cascade capable of continuous
activation of profibrotic gene expression in the target cells
[115]. However, extensive studies have shown that besides
causing a potent stimulation of the expression of genes participating in the exaggerated production and accumulation of
ECM, TGF-𝛽 is also involved in the generation of myofibroblasts through EndoMT [101–104, 116–121]. Indeed, studies
in experimentally induced cardiac hypertrophy showed that
TGF-𝛽 was a crucial mediator causing endothelial cells to
undergo EndoMT [96]. Although the detailed molecular
events and the intracellular cascades activated by TGF-𝛽 that
result in the remarkable phenotypic change of endothelial
cells to mesenchymal cells have not been entirely elucidated,
recent studies in cultured human cutaneous microvascular
endothelial cells [103], primary cultures of murine pulmonary
endothelial cells [116], and cultured pancreatic microvascular endothelial cells [121] demonstrated that both Smaddependent and Smad-independent pathways are involved.
The intracellular signaling pathways that are likely to be
involved in EndoMT induction by TGF-𝛽 are illustrated in
Figure 3.
Given the crucial role of TGF-𝛽 in the development
of tissue fibrosis and its participation in the pathogenesis of numerous fibrotic diseases, we recently examined
the mechanisms involved in the induction of EndoMT by
this pleotropic growth factor and studied the intracellular
transduction pathways involved in this process employing
primary pulmonary endothelial cells in culture [116]. In
our study, we examined the transdifferentiation of murine
pulmonary endothelial cells into mesenchymal cells in vitro
and the signaling pathways involved in this process and made
the following observations: (1) primary murine pulmonary
endothelial cells undergo EndoMT in response to TGF-𝛽
with initiation of expression of 𝛼-SMA, assembly of typical
intracellular 𝛼-SMA stress fibers, and loss of VE-cadherin in
vitro; (2) TGF-𝛽 induction of EndoMT was associated with a
strong upregulation in the expression of the transcriptional
repressor Snail-1 indicating that Snail-1 is directly involved
in TGF-𝛽-induced 𝛼-SMA expression; and (3) induction
of 𝛼-SMA expression in pulmonary endothelial cells was
mediated by the c-Abl kinase and by protein kinase c𝛿 (PKC-𝛿), as specific inhibition of their kinase activity
with imatinib mesylate and rottlerin, respectively, or by
knockdown of their corresponding transcripts with specific
siRNA abrogated the marked increase in TGF-𝛽 induced
𝛼-SMA and Snail-1 expression and protein levels. These
studies collectively showed that these effects are mediated
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Figure 3: Signaling pathways involved in EndoMT. The diagram shows the numerous putative pathways that may participate in the EndoMT
process and may be involved in SSc pathogenesis. One central pathway initiated following ligand-binding activation of the Smad-independent
TGF-𝛽 pathway causes phosphorylation of GSK-3𝛽 mediated by PKC-𝛿 and the c-Abl nonreceptor kinase. Phosphorylation of GSK-3𝛽
at serine 9 (ser9) causes its inhibition which then allows Snail-1 to enter the nucleus. Nuclear accumulation of Snail-1 results in marked
stimulation of Snail-1 expression which then leads to acquisition of the myofibroblast phenotype with stimulation of 𝛼-SMA. The inhibition
of GSK-3𝛽 ser9 phosphorylation by specific inhibition of PKC-𝛿 or c-Abl activity allows GSK-3𝛽 to phosphorylate Snail-1 targeting it for
proteosomal degradation and thus effectively abolishes the acquisition of the myofibroblastic phenotype and the fibrotic response. Other
pathways such as those involving ET-1, Wnt, NOTCH, hypoxia, and cellular stress responses may also participate although the molecular
events have not been fully elucidated. Modified from Piera-Velazquez and Jimenez [101].

by the transcriptional repressor Snail-1 [103, 116]. Snail-1 is
a zinc-finger transcription factor that forms a complex with
Smad3/Smad4. The active Smad3/Smad4/Snail-1 complex
causes potent inhibition of the expression of E-cadherin
by directly binding to specific sequences within the gene
promoter and blocking its transcription. Besides inhibition of
E-cadherin, Snail-1 induces numerous transcriptional events
that lead to the expression of a mesenchymal-cell-specific
phenotype. Snail-1 levels are regulated by complex phosphorylation events mediated by intracellular kinases including
c-Abl kinase, PKC-𝛿, PI3K, p38 MAP kinase and glycogen
synthase kinase 3𝛽 (GSK-3𝛽). The role of PKC-𝛿 and c-Abl
kinases has been demonstrated employing specific kinase
inhibitors and/or specific knockdown with small interfering
RNAs [116], whereas the role of PI3K, p38 MAPK and GSK3𝛽 was demonstrated employing specific inhibitors of the
corresponding pathways [103]. Numerous studies have shown
a crucial role of GSK-3𝛽 in the regulation of Snail-1 effects.
GSK-3𝛽 phosphorylation results in its inactivation which in
turn induces the nuclear accumulation of Snail-1 followed by
a profound increase in the expression of its corresponding
gene. In contrast, in the absence of GSK-3𝛽 phosphorylation,
the GSK-3𝛽 kinase is active and induces the proteosomal

degradation of Snail-1, thus abrogating the endothelial to
mesenchymal cellular phenotypic conversion. The role of
GSK-3𝛽 in the regulation of Snail-1 stability, and therefore, in
the expression of its potent transcriptional effects is illustrated
in Figure 3.
6.2. Regulation of EndoMT by the Wnt and NOTCH Signaling
Pathways. Although not extensively studied in EndoMT, it
has recently become apparent that several important regulatory pathways including the canonical Wnt pathway and the
NOTCH pathway may also participate in the regulation of
EndoMT as illustrated in Figure 3.
6.2.1. Wnt Signaling. The Wnt proteins comprise a large family of secreted glycoproteins with complex canonical and
noncanonical intracellular signaling pathways that play crucial roles during embryonic development and organogenesis
[122–124]. Wnt proteins and pathways have been recently
implicated in the pathogenesis of numerous diseases, including SSc and other fibrotic diseases [125–129]. TGF-𝛽 appears
to be the major factor activating the canonical Wnt pathway
[130, 131]. This process is probably mediated by a decrease
of Dickkopf-related protein 1 (Dkk-1), a potent Wnt pathway
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inhibitor, as indicated by the observations that the addition of
recombinant Dkk-1 blocked the stimulatory effects of TGF-𝛽
on the canonical Wnt pathway in fibroblasts [132, 133].
Although there is extensive published literature regarding
the role of Wnt pathway activation in the phenotypic conversion of epithelial cells into mesenchymal cells, also known
as EMT [134–137], the possibility that Wnt may participate
in EndoMT is just beginning to be explored. Indeed, a
recent study examined the role of Wnt7 and the Wnt7
antagonist Dkk-1 on EndoMT in primary aortic endothelial
cells in culture and in transgenic mice with an endothelialspecific Wnt-7b deletion [138]. The results showed that Dkk-1
inhibition of the Wnt pathway enhanced EndoMT, whereas
Wnt-7b expression preserved the endothelial cell phenotype.
6.2.2. NOTCH Signaling. The NOTCH proteins are members
of the group of proteins collectively known as morphogens
owing to their crucial roles in cell fate decisions during
morphogenesis and embryonic development, particularly in
relation to cardiovascular development and to regulation of
central nervous system polarity and vertebrate segmentation
[139, 140]. However, involvement of NOTCH proteins in
a broad spectrum of disorders is just becoming apparent
[141–147]. The role of NOTCH signaling in EndoMT was
first described by Noseda et al. [148], and it was suggested
that the NOTCH pathway may be crucial for heart valve
and cardiac cushion development and/or vascular smooth
muscle differentiation. Numerous subsequent studies have
confirmed and extended these observations and have examined the molecular mechanisms involved and the important
interactions with the TGF-𝛽 pathways [149–154]. Studies
to examine the participation of NOTCH proteins in the
EndoMT process in SSc have not been described, although
the demonstration of activation of NOTCH signaling in
affected SSc skin suggests that the NOTCH proteins may play
a role in SSc pathogenesis and thus may represent a potential
target for SSc disease modifying therapeutic approaches [155,
156].
6.3. Caveolin-1 Regulation of EndoMT. Another recently
identified mechanism of regulation and fine tuning of TGF𝛽 activity involves Caveolin-1 (Cav-1), the most important
member of a family of proteins found in lipid rafts. Cav-1
plays an important role in TGF-𝛽 signaling regulation owing
to its participation in TGF-𝛽 receptor (T𝛽R) internalization
[157–159]. T𝛽Rs are internalized both by Cav-1-associated
lipid rafts and by early endosome antigen 1 (EEA-1) nonlipid raft pathways. Non-lipid raft associated internalization increases TGF-𝛽 signaling, whereas caveolin-associated
internalization increases T𝛽R degradation, thereby effectively
decreasing or abolishing TGF-𝛽 signaling [157]. The localization of the T𝛽Rs in the EEA-1 positive compartment
is responsible for downstream Smad activation, whereas
their localization in Cav-1 containing lipid rafts has been
shown to cause subsequent receptor ubiquitination and rapid
degradation and turnover [158, 159]. Despite the important
interactions between Cav-1 and TGF-𝛽 and the numerous
studies that supported the role of Cav-1 in the pathogenesis
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of SSc [160–164], the possibility that Cav-1 may participate
in the regulation of EndoMT has not been explored in detail,
although a recent study examined the contribution of Cav-1 to
EndoMT employing Cav-1 knockout mice [165]. The results
indicated that Cav-1 may be a crucial regulator of EndoMT in
murine pulmonary endothelial cells. In these studies, it was
shown that pulmonary endothelial cells isolated from Cav1 knockout mice displayed spontaneous EndoMT and that
Cav-1 deficiency potentiated the EndoMT effect induced by
TGF-𝛽 [165].
6.4. Role of Other Growth Factors in EndoMT. The most severe clinical and pathologic manifestations of SSc are the
result of a fibrotic process characterized by the excessive and
often progressive deposition of collagen and other connective
tissue macromolecules in skin and numerous internal organs.
Numerous studies have shown that tissue fibrosis in SSc is the
result of an upregulated expression of genes encoding collagen and other extracellular matrix proteins in affected organs.
The exact mechanisms responsible for the establishment of
the fibrotic process in SSc have not been precisely determined
[2–6], although it has become very clear that several growth
factors play a crucial role [166].
Besides TGF-𝛽, the most important growth factor, involved in SSc tissue fibrosis and in EndoMT, other growth factors and profibrogenic molecules, including platelet derived
growth factors [167], vascular endothelial growth factor [168],
and insulin-derived growth factor [169], may also participate
in EndoMT although their role in this process has not
been studied to our knowledge. However, some studies
that examined the role of other profibrotic growth factors
have been described. One of the profibrotic polypeptides
shown to participate in EndoMT is endothelin-1. One study
showed that endothelial cell-derived endothelin-1 promotes
cardiac fibrosis and heart failure in diabetic hearts through
stimulation of EndoMT as these effects did not occur in
hearts from transgenic mice with endothelial cell specific
endothelin-1 deletion [170].
Connective Tissue Growth Factor (CTGF), also known as
CCN2, is another pleotropic growth factor that has emerged
as an important mediator of normal and pathological tissue
fibrotic responses [171–174] and has been suggested to play
a crucial role in SSc tissue fibrosis. TGF-𝛽 causes potent
stimulation of CTGF synthesis in fibroblasts, vascular smooth
muscle cells, and endothelial cells, and numerous studies
have shown that CTGF represents a downstream mediator
of TGF-𝛽 fibrogenic effects [175–177]. Despite the important
role of CTGF in the pathogenesis of tissue fibrosis and its
potential participation in SSc owing to the well-recognized
functional interactions with TGF-𝛽, its possible participation
in the EndoMT process has not been investigated, although a
very recent study showed that elevated levels of CTGF in SSc
microvascular endothelial cells were capable of stimulating
fibroblast activation and increased motility and invasion in
in vitro studies. Further investigation indicated that these
effects were mediated by CTGF-induced increased expression
of TGF-𝛽 in the target fibroblasts [178]. Another very recent
study demonstrated that CTGF is one of the target genes of
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Snail-1 and showed a remarkable increase in CTGF expression in endothelial cells following experimentally-induced
overexpression of Snail-1 [179].
6.5. Role of MicroRNAs in the Regulation of EndoMT. MicroRNAs (miRNAs) are small (∼22 nucleotides), evolutionarily conserved noncoding RNAs which play important roles
in the regulation of the expression of a large number of
protein coding genes at the posttranscriptional level [180–
183]. The mechanisms involved in posttranscriptional regulation of gene expression by miRNAs are complex and
require the sequence-specific complementary binding to the
3 untranslated region (UTR) of target mRNAs suppressing
their expression by either inhibiting mRNA translation or
facilitating their degradation [184–186]. Recent interest has
been devoted to elucidating their participation in tissue
fibrosis and fibrotic diseases [187–190]. Indeed, several miRNAs have been shown to be involved in SSc tissue fibrosis
[191–197], displaying either profibrotic or antifibrotic effects.
Furthermore, it has been shown that numerous miRNAs display strong modulation of their expression by TGF-𝛽 [198],
although the implications of these TGF-𝛽-miRNA interactions have not been fully elucidated. Moreover, several studies
have described potential modulatory effects of miRNA on
EMT [199], although their participation in EndoMT has not
been examined in detail. However, recent reports described
results indicating that miRNA21 partially mediated the TGF𝛽-induced EndoMT in human umbilical vein endothelial
cells [200] and that several miRNAs were either increased
or decreased during TGF-𝛽2-induced EndoMT in murine
cardiac endothelial cells [120].

7. Conclusions and Future Directions
Scleroderma or Systemic Sclerosis (SSc) is a systemic autoimmune disease of unknown etiology characterized by
progressive fibrosis of skin and multiple internal organs
and severe alterations in the microvasculature [1]. SSc is
the third most common systemic inflammatory autoimmune
disease and has the highest case-specific mortality among
this group of idiopathic disorders. Whereas remarkable
therapeutic advances have recently been accomplished for
Rheumatoid Arthritis and Systemic Lupus Erythematosus,
there is currently no effective disease-modifying therapy
for SSc. Therefore, there is an urgent unmet need for
the development of effective disease-modifying therapies
to improve the devastating health consequences and high
mortality caused by the disease. The effector cells ultimately
responsible for the severe fibroproliferative process in SSc
are activated myofibroblasts. These cells display very active
protein synthesis producing increased amounts of ECM
proteins and acquiring a motile and contractile phenotype
expressing a high level of 𝛼-SMA [12–14]. Although it is
widely recognized that there are numerous inflammatory and
immunological events in the pathogenesis of SSc, myofibroblasts have been recognized as the crucial determinant of the
fibrotic process in SSc and other fibrotic disorders [6, 11–13,
201–203]. Furthermore, their accumulation in affected tissues
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and the persistence of their elevated biosynthetic functions
are the primary determinants of the extent and severity of
the clinical manifestations in SSc, and of its clinical course,
response to therapy, prognosis, and overall mortality. Thus,
activated myofibroblasts have become an important target for
SSc disease-modifying therapeutic approaches [204–206].
Extensive research studies have shown that these cells
originate from several sources [94, 207], including expansion
and phenotypic activation of resident tissue fibroblasts and
migration and tissue accumulation of bone marrow-derived
circulating fibrocytes, or from epithelial cells which have
undergone EMT. More recent studies, however, have demonstrated that endothelial cells are also capable of undergoing
a phenotypic change to activated mesenchymal cells in a
complex process known as EndoMT. Although there are very
few studies that have examined the possible participation of
EndoMT in the initiation and progression of the fibrotic and
fibroproliferative processes in SSc, it is expected that given
its potential importance in the pathogenesis of this currently
incurable disease this area of investigation may attract further
scientific attention.
Despite the relatively recent research interest in the role
of EndoMT in the SSc pathogenesis, important components
of the complex pathway of TGF-𝛽-induced EndoMT and
the molecular mechanisms involved in the generation of
activated tissue myofibroblasts have already been identified.
These observations suggest that targeting components of
these pathways may be a feasible therapeutic goal to modify
crucial steps in the development of SSc fibroproliferative
vasculopathy [208]. Furthermore, the important role that
miRNAs have been shown to play in the regulation of gene
expression has clearly opened the possibility of developing
a novel therapeutic approach for SSc by targeting these
extremely versatile noncoding RNA species. Obviously, subsequent preclinical studies employing suitable animal models
will be required to further support the potential therapeutic
role of EndoMT and/or miRNA modulation for the fibrosis
and proliferative vasculopathy of SSc.
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and L. Guillevin, “Scleroderma renal crisis: a rare but severe
complication of systemic sclerosis,” Clinical Reviews in Allergy
and Immunology, vol. 40, no. 2, pp. 84–91, 2011.
[27] C. P. Denton and C. M. Black, “Pulmonary hypertension in
systemic sclerosis,” Rheumatic Disease Clinics of North America,
vol. 29, no. 2, pp. 335–349, 2003.
[28] A. Ramirez and J. Varga, “Pulmonary arterial hypertension
in systematic sclerosis: clinical manifestations, pathophysiology, evaluation, and management,” Treatments in Respiratory
Medicine, vol. 3, no. 6, pp. 339–352, 2004.
[29] S. Chatterjee, “Pulmonary hypertension in systemic sclerosis,”
Seminars in Arthritis and Rheumatism, vol. 41, no. 1, pp. 19–37,
2011.
[30] M. Cutolo, A. Sulli, and V. Smith, “Assessing microvascular
changes in systemic sclerosis diagnosis and management,”
Nature Reviews Rheumatology, vol. 6, no. 10, pp. 578–587, 2010.
[31] W. Grassi, P. D. Medico, F. Izzo, and C. Cervini, “Microvascular
involvement in systemic sclerosis: capillaroscopic findings,”
Seminars in Arthritis and Rheumatism, vol. 30, no. 6, pp. 397–
402, 2001.
[32] A. A. Shah, F. M. Wigley, and L. K. Hummers, “Telangiectases in
scleroderma: a potential clinical marker of pulmonary arterial
hypertension,” Journal of Rheumatology, vol. 37, no. 1, pp. 98–
104, 2010.
[33] M. M. El-Omar, A. P. Jenkins, K. Hollowood, A. K. Banerjee,
and R. P. H. Thompson, “Gastric telangiectasis: a rare cause of
severe blood loss in CREST syndrome,” Postgraduate Medical
Journal, vol. 70, no. 822, pp. 302–304, 1994.
[34] B. Jharap, L. G. Koudstaal, E. A. Neefjes-Borst, and S. J. B. van
Weyenberg, “Colonic telangiectasias in progressive systemic
sclerosis,” Endoscopy, vol. 44, supplement 2, pp. E42–E43, 2012.
[35] E. V. Lally and S. A. Jimenez, “Impotence in progressive systemic sclerosis,” Annals of Internal Medicine, vol. 95, no. 2, pp.
150–153, 1981.
[36] S. Sukenik, J. Horowitz, D. Buskila, J. M. Abarbanel, L. Lismer,
and I. Avinoach, “Impotence in systemic sclerosis,” Annals of
Internal Medicine, vol. 106, no. 6, pp. 910–911, 1987.
[37] C. Foocharoen, A. Tyndall, E. Hachulla et al., “Erectile dysfunction is frequent in systemic sclerosis and associated with severe
disease: a study of the EULAR scleroderma trial and research
group,” Arthritis Research and Therapy, vol. 14, no. 1, article R37,
2012.
[38] C. T. Derk and S. A. Jimenez, “Acute myocardial infarction in
systemic sclerosis patients: a case series,” Clinical Rheumatology,
vol. 26, no. 6, pp. 965–968, 2007.
[39] Y. Allanore and C. Meune, “Primary myocardial involvement in
systemic sclerosis: evidence for a microvascular origin,” Clinical

10

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

ISRN Rheumatology
and Experimental Rheumatology, vol. 28, no. 5, pp. S48–S53,
2010.
M. Watson, R. J. Hally, P. A. McCue, J. Varga, and S. A.
Jiménez, “Gastric antral vascular ectasia (watermelon stomach)
in patients with systemic sclerosis,” Arthritis and Rheumatism,
vol. 39, no. 2, pp. 341–346, 1996.
K. M. Ingraham, M. S. O’Brien, M. A. X. Shenin, C. T. Derk, and
V. D. Steen, “Gastric antral vascular ectasia in systemic sclerosis:
demographics and disease predictors,” Journal of Rheumatology,
vol. 37, no. 3, pp. 603–607, 2010.
E. W. Hung, M. D. Mayes, R. Sharif, S. Assassi, V. I. Machicao,
and C. Hosing, “Gastric antral vascular ectasia and its clinical
correlates in patients with early diffuse systemic sclerosis in the
SCOT trial,” Journal of Rheumatology, vol. 40, no. 4, pp. 455–
460, 2013.
J. Busquets, Y. Lee, L. Santamarina et al., “Acute retinal artery
occlusion in systemic sclerosis: a rare manifestation of systemic
sclerosis fibroproliferative vasculopathy,” Seminars in Arthritis
and Rheumatism, 2013.
M. Minasian, M. Stanford, E. Graham, C. P. Denton, and
C. Black, “Bilateral ischaemic retinal vasculopathy in scleroderma,” The British Journal of Ophthalmology, vol. 89, no. 8, pp.
1064–1065, 2005.
M. H. Taylor, J. A. McFadden, M. B. Bolster, and R. M. Silver,
“Ulnar artery involvement in systemic sclerosis (scleroderma),”
Journal of Rheumatology, vol. 29, no. 1, pp. 102–106, 2002.
P. Youssef, H. Englert, and J. Bertouch, “Large vessel occlusive
disease associated with CREST syndrome and scleroderma,”
Annals of the Rheumatic Diseases, vol. 52, no. 6, pp. 464–466,
1993.
U. Müller-Ladner, O. Distler, L. Ibba-Manneschi, E. Neumann,
and S. Gay, “Mechanisms of vascular damage in systemic
sclerosis,” Autoimmunity, vol. 42, no. 7, pp. 587–595, 2009.
D. Abraham and O. Distler, “How does endothelial cell injury
start? The role of endothelin in systemic sclerosis,” Arthritis
Research and Therapy, vol. 9, supplement 2, article S2, 2007.
J. P. Pandey and E. C. LeRoy, “Human cytomegalovirus and
the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis,” Arthritis
and Rheumatism, vol. 41, no. 1, pp. 10–15, 1998.
M. Neidhart, S. Kuchen, O. Distler et al., “Increased serum levels
of antibodies against human cytomegalovirus and prevalence of
autoantibodies in systemic sclerosis,” Arthritis and Rheumatism,
vol. 42, pp. 389–392, 1999.
Y. Renaudineau, R. Revelen, Y. Levy et al., “Anti-endothelial
cell antibodies in systemic sclerosis,” Clinical and Diagnostic
Laboratory Immunology, vol. 6, no. 2, pp. 156–160, 1999.
F. Drenk and H. R. G. Deicher, “Pathophysiological effects of
endothelial cytotoxic activity derived from sera of patients with
progressive systemic sclerosis,” Journal of Rheumatology, vol. 15,
no. 3, pp. 468–474, 1988.
N. Del Papa, G. Colombo, N. Fracchiolla et al., “Circulating
endothelial cells as a marker of ongoing vascular disease in
systemic sclerosis,” Arthritis and Rheumatism, vol. 50, no. 4, pp.
1296–1304, 2004.
J. Avouac, F. Juin, J. Wipff et al., “Circulating endothelial
progenitor cells in systemic sclerosis: association with disease
severity,” Annals of the Rheumatic Diseases, vol. 67, no. 10, pp.
1455–1460, 2008.
Y. Allanore, F. Batteux, J. Avouac, N. Assous, B. Weill, and A.
Kahan, “Levels of circulating endothelial progenitor cells in

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[66]

[67]

[68]

[69]

[70]

[71]

systemic sclerosis,” Clinical and Experimental Rheumatology,
vol. 25, no. 1, pp. 60–66, 2007.
A. Kuryliszyn-Moskal, P. A. Klimiuk, and S. Sierakowski,
“Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular
endothelial growth factor (VEGF) and endothelin-1 in patients
with systemic sclerosis: relationship to organ systemic involvement,” Clinical Rheumatology, vol. 24, no. 2, pp. 111–116, 2005.
G. N. Andersen, K. Caidahl, E. Kazzam et al., “Correlation
between increased nitric oxide production and markers of
endothelial activation in systemic sclerosis: findings with the
soluble adhesion molecules E-selectin, intercellular adhesion
molecule 1, and vascular cell adhesion molecule 1,” Arthritis and
Rheumatism, vol. 43, no. 5, pp. 1085–1093, 2000.
M. J. Mulligan-Kehoe and M. Simons, “Vascular disease in scleroderma: angiogenesis and vascular repair,” Rheumatic Disease
Clinics of North America, vol. 34, no. 1, pp. 73–79, 2008.
M. M. Cerinic, G. Valentini, G. G. Sorano et al., “Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in
systemic sclerosis,” Seminars in Arthritis and Rheumatism, vol.
32, no. 5, pp. 285–295, 2003.
K. R. Stenmark, K. A. Fagan, and M. G. Frid, “Hypoxia-induced
pulmonary vascular remodeling: cellular and molecular mechanisms,” Circulation Research, vol. 99, no. 7, pp. 675–691, 2006.
C. Beyer, G. Schett, S. Gay, O. Distler, and J. H. W. Distler,
“Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis,”
Arthritis Research & Therapy, vol. 11, no. 2, p. 220, 2009.
M. E. Anderson, T. L. Moore, S. Hollis, S. Clark, M. I. V. Jayson,
and A. L. Herrick, “Endothelial-dependent vasodilatation is
impaired in patients with systemic sclerosis, as assessed by low
dose iontophoresis,” Clinical and Experimental Rheumatology,
vol. 21, no. 3, article 403, 2003.
R. Livi, L. Teghini, S. Generini, and M. Matucci-Cerinic,
“The loss of endothelium-dependent vascular tone control in
systemic sclerosis,” Chest, vol. 119, no. 2, pp. 672–673, 2001.
B. Kahaleh and M. Matucci-Cerinic, “Raynaud’s phenomenon
and scleroderma: dysregulated neuroendothelial control of
vascular tone,” Arthritis and Rheumatism, vol. 38, no. 1, pp. 1–
4, 1995.
J. Cailes, S. Winter, R. M. du Bois, and T. W. Evans, “Defective
endothelially mediated pulmonary vasodilation in systemic
sclerosis,” Chest, vol. 114, no. 1, pp. 178–184, 1998.
A. Leask, “The role of endothelin-1 signaling in the fibrosis
observed in systemic sclerosis,” Pharmacological Research, vol.
63, no. 6, pp. 502–503, 2011.
N. Giordano, P. Papakostas, G. Pecetti, and R. Nuti, “Cytokine
modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis,” Journal of Biological Regulators and
Homeostatic Agents, vol. 25, no. 4, pp. 487–492, 2011.
K. Yamane, H. Kashiwagi, N. Suzuki et al., “Elevated plasma
levels of endothelin-1 in systemic sclerosis,” Arthritis and
Rheumatism, vol. 34, no. 2, pp. 243–244, 1991.
K. Yamane, T. Miyauchi, N. Suzuki et al., “Significance of plasma
endothelin-1 levels in patients with systemic sclerosis,” Journal
of Rheumatology, vol. 19, no. 10, pp. 1566–1571, 1992.
A. D. Cambrey, N. K. Harrison, K. E. Dawes et al., “Increased
levels of endothelin-1 in bronchoalveolar lavage fluid from
patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro,” The American Journal of Respiratory Cell
and Molecular Biology, vol. 11, no. 4, pp. 439–445, 1994.
R. Vancheeswaran, T. Magoulas, G. Efrat et al., “Circulating
endothelin-1 levels in systemic sclerosis subsets—a marker of

ISRN Rheumatology

[72]

[73]

[74]

[75]

[76]

[77]

[78]

[79]

[80]

[81]

[82]

[83]

[84]

[85]

[86]

fibrosis or vasular dysfunction?” Journal of Rheumatology, vol.
21, no. 10, pp. 1838–1844, 1994.
S. Morelli, C. Ferri, E. Polettini et al., “Plasma endothelin-1
levels, pulmonary hypertension, and lung fibrosis in patients
with systemic sclerosis,” The American Journal of Medicine, vol.
99, no. 3, pp. 255–260, 1995.
S. Xu, C. P. Denton, A. Holmes, M. R. Dashwood, D. J. Abraham,
and C. M. Black, “Endothelins: effect on matrix biosynthesis and
proliferation in normal and scleroderma fibroblasts,” Journal
of Cardiovascular Pharmacology, vol. 31, no. 1, pp. S360–S363,
1998.
X. Shi-Wen, C. P. Denton, M. R. Dashwood et al., “Fibroblast
matrix gene expression and connective tissue remodeling: role
of endothelin-1,” Journal of Investigative Dermatology, vol. 116,
no. 3, pp. 417–425, 2001.
X. Shi-Wen, E. A. Renzoni, L. Kennedy et al., “Endogenous
endothelin-1 signaling contributes to type I collagen and CCN2
overexpression in fibrotic fibroblasts,” Matrix Biology, vol. 26,
no. 8, pp. 625–632, 2007.
X. Shi-wen, L. Kennedy, E. A. Renzoni et al., “Endothelin is a
downstream mediator of profibrotic responses to transforming
growth factor 𝛽 in human lung fibroblasts,” Arthritis and
Rheumatism, vol. 56, no. 12, pp. 4189–4194, 2007.
I. Chrobak, S. Lenna, L. Stawski, and M. Trojanowska, “Interferon-𝛾 promotes vascular remodeling in human microvascular
endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) 𝛽2,” Journal of Cellular Physiology,
vol. 228, no. 8, pp. 1774–1783, 2013.
A. E. Koch and O. Distler, “Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis
and systemic sclerosis,” Arthritis Research and Therapy, vol. 9,
supplement 2, article S3, 2007.
J. H. W. Distler, S. Gay, and O. Distler, “Angiogenesis and
vasculogenesis in systemic sclerosis,” Rheumatology, vol. 45, no.
3, pp. iii26–iii27, 2006.
J. Wipff, J. Avouac, D. Borderie et al., “Disturbed angiogenesis
in systemic sclerosis: high levels of soluble endoglin,” Rheumatology, vol. 47, no. 7, pp. 972–975, 2008.
N. Del Papa, N. Quirici, D. Soligo et al., “Bone marrow
endothelial progenitors are defective in systemic sclerosis,”
Arthritis and Rheumatism, vol. 54, no. 8, pp. 2605–2615, 2006.
M. Kuwana, Y. Okazaki, H. Yasuoka, Y. Kawakami, and Y. Ikeda,
“Defective vasculogenesis in systemic sclerosis,” The Lancet, vol.
364, no. 9434, pp. 603–610, 2004.
O. Distler, J. H. W. Distler, A. Scheid et al., “Uncontrolled
expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with
systemic sclerosis,” Circulation Research, vol. 95, no. 1, pp. 109–
116, 2004.
T. Nevskaya, S. Bykovskaia, E. Lyssuk et al., “Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired
angiogenesis and cardiovascular manifestations,” Clinical and
Experimental Rheumatology, vol. 26, no. 3, pp. 421–429, 2008.
P. Cipriani, S. Guiducci, I. Miniati et al., “Impairment of
endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of
systemic sclerosis,” Arthritis and Rheumatism, vol. 56, no. 6, pp.
1994–2004, 2007.
J. N. Fleming and S. M. Schwartz, “The pathology of scleroderma vascular disease,” Rheumatic Disease Clinics of North
America, vol. 34, no. 1, pp. 41–55, 2008.

11
[87] F. J. de Lange, A. F. M. Moorman, R. H. Anderson et al., “Lineage
and morphogenetic analysis of the cardiac valves,” Circulation
Research, vol. 95, no. 6, pp. 645–654, 2004.
[88] E. Arciniegas, C. Y. Neves, L. M. Carrillo, E. A. Zambrano, and
R. Ramı́rez, “Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development,” Endothelium,
vol. 12, no. 4, pp. 193–200, 2005.
[89] A. de Vlaming, K. Sauls, Z. Hajdu et al., “Atrioventricular valve
development: new perspectives on an old theme,” Differentiation, vol. 84, no. 1, pp. 103–116, 2012.
[90] S. Piera-Velazquez, Z. Li, and S. A. Jimenez, “Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis
of fibrotic disorders,” The American Journal of Pathology, vol.
179, no. 3, pp. 1074–1080, 2011.
[91] J. He, Y. Xu, and K. Kanasaki, “Role of endothelial-tomesenchymal transition in renal fibrosis of chronic kidney
disease,” Clinical and Experimental Nephrology, vol. 17, no. 4, pp.
488–497, 2013.
[92] J. Li and J. F. Bertram, “Endothelial-myofibroblast transition, a
new player in diabetic renal fibrosis,” Nephrology, vol. 15, no. 5,
pp. 507–512, 2010.
[93] F. Rieder, S. P. Kessler, G. A. West et al., “Inflammation-induced
endothelial-to-mesenchymal transition: a novel mechanism of
intestinal fibrosis,” The American Journal of Pathology, vol. 179,
no. 5, pp. 2660–2673, 2011.
[94] V. S. Lebleu, G. Taduri, J. O’Connell et al., “Origin and function
of myofibroblasts in kidney fibrosis,” Nature Medicine, vol. 19,
no. 8, pp. 1047–1053, 2013.
[95] E. M. Zeisberg, S. E. Potenta, H. Sugimoto, M. Zeisberg, and R.
Kalluri, “Fibroblasts in kidney fibrosis emerge via endothelialto-mesenchymal transition,” Journal of the American Society of
Nephrology, vol. 19, no. 12, pp. 2282–2287, 2008.
[96] E. M. Zeisberg, O. Tarnavski, M. Zeisberg et al., “Endothelialto-mesenchymal transition contributes to cardiac fibrosis,”
Nature Medicine, vol. 13, no. 8, pp. 952–961, 2007.
[97] A. Kizu, D. Medici, and R. Kalluri, “Endothelial-mesenchymal
transition as a novel mechanism for generating myofibroblasts
during diabetic nephropathy,” The American Journal of Pathology, vol. 175, no. 4, pp. 1371–1373, 2009.
[98] S. Speca, I. Giusti, F. Rieder, and G. Latella, “Cellular and
molecular mechanisms of intestinal fibrosis,” World Journal of
Gastroenterology, vol. 18, no. 28, pp. 3635–3661, 2012.
[99] Y. Sato and Y. Nakanuma, “Role of endothelial-mesenchymal
transition in idiopathic portal hypertension,” Histology and
Histopathology, vol. 28, pp. 145–154, 2013.
[100] E. Arciniegas, M. G. Frid, I. S. Douglas, and K. R. Stenmark, “Perspectives on endothelial-to-mesenchymal transition:
potential contribution to vascular remodeling in chronic pulmonary hypertension,” The American Journal of Physiology—
Lung Cellular and Molecular Physiology, vol. 293, no. 1, pp. L1–
L8, 2007.
[101] S. Piera-Velazquez and S. A. Jimenez, “Molecular mechanisms
of endothelial to mesenchymal cell transition (EndoMT) in
experimentally induced fibrotic diseases,” Fibrogenesis and Tissue Repair, vol. 5, supplement 1, article S7, 2012.
[102] M. Goumans, Z. Liu, and P. T. Dijke, “TGF-𝛽 signaling in
vascular biology and dysfunction,” Cell Research, vol. 19, no. 1,
pp. 116–127, 2009.
[103] D. Medici, S. Potenta, and R. Kalluri, “Transforming growth
factor-𝛽2 promotes Snail-mediated endothelial—mesenchymal

12

[104]

[105]

[106]

[107]

[108]

[109]

[110]

[111]

[112]

[113]

[114]

[115]

[116]

[117]

[118]

ISRN Rheumatology
transition through convergence of Smad-dependent and Smadindependent signalling,” Biochemical Journal, vol. 437, no. 3, pp.
515–520, 2011.
L. A. van Meeteren and P. T. Dijke, “Regulation of endothelial
cell plasticity by TGF-𝛽,” Cell and Tissue Research, vol. 347, no.
1, pp. 177–186, 2012.
M. B. Sporn, A. B. Roberts, L. M. Wakefield, and R. K. Assoian,
“Transforming growth factor factor-𝛽: biological function and
chemical structure,” Science, vol. 233, no. 4763, pp. 532–534,
1986.
A. B. Roberts, K. C. Flanders, U. I. Heine et al., “Transforming
growth factor-beta: multifunctional regulator of differentiation
and development,” Philosophical transactions of the Royal Society of London B, vol. 327, no. 1239, pp. 145–154, 1990.
G. C. Blobe, W. P. Schiemann, and H. F. Lodish, “Role of
transforming growth factor 𝛽 in human disease,” The New
England Journal of Medicine, vol. 342, no. 18, pp. 1350–1358,
2000.
W. A. Border and N. A. Noble, “Transforming growth factor 𝛽
in tissue fibrosis,” The New England Journal of Medicine, vol. 331,
no. 19, pp. 1286–1292, 1994.
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